vs

Side-by-side financial comparison of PAR PACIFIC HOLDINGS, INC. (PARR) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

PAR PACIFIC HOLDINGS, INC. is the larger business by last-quarter revenue ($1.8B vs $961.0M, roughly 1.9× DENTSPLY SIRONA Inc.). PAR PACIFIC HOLDINGS, INC. runs the higher net margin — 4.3% vs -15.2%, a 19.5% gap on every dollar of revenue. On growth, DENTSPLY SIRONA Inc. posted the faster year-over-year revenue change (6.2% vs -1.0%). PAR PACIFIC HOLDINGS, INC. produced more free cash flow last quarter ($66.3M vs $60.0M). Over the past eight quarters, DENTSPLY SIRONA Inc.'s revenue compounded faster (0.4% CAGR vs -4.3%).

Par Pacific Holdings is a Houston-based American oil and gas exploration and production company. Known as Par Petroleum Corporation after it emerged from bankruptcy, it was renamed Par Pacific Holdings on October 20, 2015. As of 2017 it was a Fortune 1000 corporation.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

PARR vs XRAY — Head-to-Head

Bigger by revenue
PARR
PARR
1.9× larger
PARR
$1.8B
$961.0M
XRAY
Growing faster (revenue YoY)
XRAY
XRAY
+7.2% gap
XRAY
6.2%
-1.0%
PARR
Higher net margin
PARR
PARR
19.5% more per $
PARR
4.3%
-15.2%
XRAY
More free cash flow
PARR
PARR
$6.3M more FCF
PARR
$66.3M
$60.0M
XRAY
Faster 2-yr revenue CAGR
XRAY
XRAY
Annualised
XRAY
0.4%
-4.3%
PARR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PARR
PARR
XRAY
XRAY
Revenue
$1.8B
$961.0M
Net Profit
$77.7M
$-146.0M
Gross Margin
46.1%
Operating Margin
5.5%
-14.5%
Net Margin
4.3%
-15.2%
Revenue YoY
-1.0%
6.2%
Net Profit YoY
239.5%
66.0%
EPS (diluted)
$1.40
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PARR
PARR
XRAY
XRAY
Q4 25
$1.8B
$961.0M
Q3 25
$2.0B
$904.0M
Q2 25
$1.9B
$936.0M
Q1 25
$1.7B
$879.0M
Q4 24
$1.8B
$905.0M
Q3 24
$2.1B
$951.0M
Q2 24
$2.0B
$984.0M
Q1 24
$2.0B
$953.0M
Net Profit
PARR
PARR
XRAY
XRAY
Q4 25
$77.7M
$-146.0M
Q3 25
$262.6M
$-427.0M
Q2 25
$59.5M
$-45.0M
Q1 25
$-30.4M
$20.0M
Q4 24
$-55.7M
$-430.0M
Q3 24
$7.5M
$-494.0M
Q2 24
$18.6M
$-4.0M
Q1 24
$-3.8M
$18.0M
Gross Margin
PARR
PARR
XRAY
XRAY
Q4 25
46.1%
Q3 25
48.8%
Q2 25
52.4%
Q1 25
53.0%
Q4 24
49.3%
Q3 24
52.1%
Q2 24
51.9%
Q1 24
53.1%
Operating Margin
PARR
PARR
XRAY
XRAY
Q4 25
5.5%
-14.5%
Q3 25
17.8%
-24.1%
Q2 25
5.1%
-13.7%
Q1 25
-0.9%
7.2%
Q4 24
-2.6%
-56.2%
Q3 24
1.7%
-48.6%
Q2 24
2.4%
5.1%
Q1 24
0.5%
4.4%
Net Margin
PARR
PARR
XRAY
XRAY
Q4 25
4.3%
-15.2%
Q3 25
13.0%
-47.2%
Q2 25
3.1%
-4.8%
Q1 25
-1.7%
2.3%
Q4 24
-3.0%
-47.5%
Q3 24
0.3%
-51.9%
Q2 24
0.9%
-0.4%
Q1 24
-0.2%
1.9%
EPS (diluted)
PARR
PARR
XRAY
XRAY
Q4 25
$1.40
$-0.74
Q3 25
$5.16
$-2.14
Q2 25
$1.17
$-0.22
Q1 25
$-0.57
$0.10
Q4 24
$-0.98
$-2.09
Q3 24
$0.13
$-2.46
Q2 24
$0.32
$-0.02
Q1 24
$-0.06
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PARR
PARR
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$164.1M
$326.0M
Total DebtLower is stronger
$802.9M
$2.3B
Stockholders' EquityBook value
$1.5B
$1.3B
Total Assets
$3.8B
$5.4B
Debt / EquityLower = less leverage
0.53×
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PARR
PARR
XRAY
XRAY
Q4 25
$164.1M
$326.0M
Q3 25
$159.1M
$363.0M
Q2 25
$169.2M
$359.0M
Q1 25
$133.7M
$398.0M
Q4 24
$191.9M
$272.0M
Q3 24
$183.0M
$296.0M
Q2 24
$179.7M
$279.0M
Q1 24
$228.3M
$291.0M
Total Debt
PARR
PARR
XRAY
XRAY
Q4 25
$802.9M
$2.3B
Q3 25
$967.1M
Q2 25
$1.1B
Q1 25
$1.2B
Q4 24
$1.1B
$1.7B
Q3 24
$1.0B
Q2 24
$1.1B
Q1 24
$639.5M
Stockholders' Equity
PARR
PARR
XRAY
XRAY
Q4 25
$1.5B
$1.3B
Q3 25
$1.4B
$1.5B
Q2 25
$1.1B
$2.0B
Q1 25
$1.1B
$2.0B
Q4 24
$1.2B
$1.9B
Q3 24
$1.3B
$2.5B
Q2 24
$1.3B
$3.1B
Q1 24
$1.3B
$3.3B
Total Assets
PARR
PARR
XRAY
XRAY
Q4 25
$3.8B
$5.4B
Q3 25
$4.1B
$5.7B
Q2 25
$3.9B
$6.1B
Q1 25
$3.8B
$6.0B
Q4 24
$3.8B
$5.8B
Q3 24
$3.9B
$6.6B
Q2 24
$3.9B
$6.9B
Q1 24
$3.8B
$7.1B
Debt / Equity
PARR
PARR
XRAY
XRAY
Q4 25
0.53×
1.70×
Q3 25
0.69×
Q2 25
0.97×
Q1 25
1.04×
Q4 24
0.93×
0.90×
Q3 24
0.83×
Q2 24
0.84×
Q1 24
0.49×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PARR
PARR
XRAY
XRAY
Operating Cash FlowLast quarter
$93.8M
$101.0M
Free Cash FlowOCF − Capex
$66.3M
$60.0M
FCF MarginFCF / Revenue
3.7%
6.2%
Capex IntensityCapex / Revenue
1.5%
4.3%
Cash ConversionOCF / Net Profit
1.21×
TTM Free Cash FlowTrailing 4 quarters
$296.5M
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PARR
PARR
XRAY
XRAY
Q4 25
$93.8M
$101.0M
Q3 25
$219.4M
$79.0M
Q2 25
$133.6M
$48.0M
Q1 25
$-1.4M
$7.0M
Q4 24
$-15.5M
$87.0M
Q3 24
$78.5M
$141.0M
Q2 24
$-4.7M
$208.0M
Q1 24
$25.4M
$25.0M
Free Cash Flow
PARR
PARR
XRAY
XRAY
Q4 25
$66.3M
$60.0M
Q3 25
$187.1M
$40.0M
Q2 25
$85.5M
$16.0M
Q1 25
$-42.3M
$-12.0M
Q4 24
$-63.1M
$36.0M
Q3 24
$50.2M
$98.0M
Q2 24
$-41.6M
$156.0M
Q1 24
$2.8M
$-9.0M
FCF Margin
PARR
PARR
XRAY
XRAY
Q4 25
3.7%
6.2%
Q3 25
9.3%
4.4%
Q2 25
4.5%
1.7%
Q1 25
-2.4%
-1.4%
Q4 24
-3.4%
4.0%
Q3 24
2.3%
10.3%
Q2 24
-2.1%
15.9%
Q1 24
0.1%
-0.9%
Capex Intensity
PARR
PARR
XRAY
XRAY
Q4 25
1.5%
4.3%
Q3 25
1.6%
4.3%
Q2 25
2.5%
3.4%
Q1 25
2.3%
2.2%
Q4 24
2.6%
5.6%
Q3 24
1.3%
4.5%
Q2 24
1.8%
5.3%
Q1 24
1.1%
3.6%
Cash Conversion
PARR
PARR
XRAY
XRAY
Q4 25
1.21×
Q3 25
0.84×
Q2 25
2.25×
Q1 25
0.35×
Q4 24
Q3 24
10.48×
Q2 24
-0.25×
Q1 24
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PARR
PARR

Distillates$750.6M41%
Gasoline$603.9M33%
Other Refined Products$348.8M19%
Logistics$73.7M4%
Other Revenues$44.8M2%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons